StressCovidV1, PubMed, Curation, bibRecord, 000545

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Identifieur interne : 000545 ( PubMed/Curation ); précédent : 000544; suivant : 000546

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Auteurs : Benjamin Petsch [Allemagne] ; Margit Schnee ; Annette B. Vogel ; Elke Lange ; Bernd Hoffmann ; Daniel Voss ; Thomas Schlake ; Andreas Thess ; Karl-Josef Kallen ; Lothar Stitz ; Thomas Kramps

Source :

Nature biotechnology [ 1546-1696 ] ; 2012.

RBID : pubmed:23159882

Descripteurs français

English descriptors

KwdEn :
- Aging (immunology), Animals, Animals, Newborn, B-Lymphocytes (immunology), Biotechnology, Cross Protection, Female, Ferrets, Humans, Influenza A virus (genetics), Influenza A virus (immunology), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Inbred DBA, Molecular Sequence Data, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), RNA, Messenger (genetics), RNA, Messenger (immunology), RNA, Viral (genetics), RNA, Viral (immunology), Rats, Rats, Inbred Lew, Sus scrofa, T-Lymphocytes (immunology), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology).
MESH :
- chemical , genetics : Influenza Vaccines, RNA, Messenger, RNA, Viral, Vaccines, Synthetic.
- genetics : Influenza A virus.
- immunology : Aging, B-Lymphocytes, Influenza A virus, Influenza Vaccines, Orthomyxoviridae Infections, RNA, Messenger, RNA, Viral, T-Lymphocytes, Vaccines, Synthetic.
- prevention & control : Orthomyxoviridae Infections.
- Animals, Animals, Newborn, Biotechnology, Cross Protection, Female, Ferrets, Humans, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Inbred DBA, Molecular Sequence Data, Rats, Rats, Inbred Lew, Sus scrofa.

Abstract

Despite substantial improvements, influenza vaccine production-and availability-remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.

DOI: 10.1038/nbt.2436
PubMed: 23159882

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000547

Links to Exploration step

pubmed:23159882

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.</title>
<author><name sortKey="Petsch, Benjamin" sort="Petsch, Benjamin" uniqKey="Petsch B" first="Benjamin" last="Petsch">Benjamin Petsch</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Immunology, Friedrich-Loeffler-Institut, Tübingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Immunology, Friedrich-Loeffler-Institut, Tübingen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schnee, Margit" sort="Schnee, Margit" uniqKey="Schnee M" first="Margit" last="Schnee">Margit Schnee</name>
</author>
<author><name sortKey="Vogel, Annette B" sort="Vogel, Annette B" uniqKey="Vogel A" first="Annette B" last="Vogel">Annette B. Vogel</name>
</author>
<author><name sortKey="Lange, Elke" sort="Lange, Elke" uniqKey="Lange E" first="Elke" last="Lange">Elke Lange</name>
</author>
<author><name sortKey="Hoffmann, Bernd" sort="Hoffmann, Bernd" uniqKey="Hoffmann B" first="Bernd" last="Hoffmann">Bernd Hoffmann</name>
</author>
<author><name sortKey="Voss, Daniel" sort="Voss, Daniel" uniqKey="Voss D" first="Daniel" last="Voss">Daniel Voss</name>
</author>
<author><name sortKey="Schlake, Thomas" sort="Schlake, Thomas" uniqKey="Schlake T" first="Thomas" last="Schlake">Thomas Schlake</name>
</author>
<author><name sortKey="Thess, Andreas" sort="Thess, Andreas" uniqKey="Thess A" first="Andreas" last="Thess">Andreas Thess</name>
</author>
<author><name sortKey="Kallen, Karl Josef" sort="Kallen, Karl Josef" uniqKey="Kallen K" first="Karl-Josef" last="Kallen">Karl-Josef Kallen</name>
</author>
<author><name sortKey="Stitz, Lothar" sort="Stitz, Lothar" uniqKey="Stitz L" first="Lothar" last="Stitz">Lothar Stitz</name>
</author>
<author><name sortKey="Kramps, Thomas" sort="Kramps, Thomas" uniqKey="Kramps T" first="Thomas" last="Kramps">Thomas Kramps</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:23159882</idno>
<idno type="pmid">23159882</idno>
<idno type="doi">10.1038/nbt.2436</idno>
<idno type="wicri:Area/PubMed/Corpus">000547</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000547</idno>
<idno type="wicri:Area/PubMed/Curation">000545</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000545</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.</title>
<author><name sortKey="Petsch, Benjamin" sort="Petsch, Benjamin" uniqKey="Petsch B" first="Benjamin" last="Petsch">Benjamin Petsch</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Immunology, Friedrich-Loeffler-Institut, Tübingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Immunology, Friedrich-Loeffler-Institut, Tübingen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schnee, Margit" sort="Schnee, Margit" uniqKey="Schnee M" first="Margit" last="Schnee">Margit Schnee</name>
</author>
<author><name sortKey="Vogel, Annette B" sort="Vogel, Annette B" uniqKey="Vogel A" first="Annette B" last="Vogel">Annette B. Vogel</name>
</author>
<author><name sortKey="Lange, Elke" sort="Lange, Elke" uniqKey="Lange E" first="Elke" last="Lange">Elke Lange</name>
</author>
<author><name sortKey="Hoffmann, Bernd" sort="Hoffmann, Bernd" uniqKey="Hoffmann B" first="Bernd" last="Hoffmann">Bernd Hoffmann</name>
</author>
<author><name sortKey="Voss, Daniel" sort="Voss, Daniel" uniqKey="Voss D" first="Daniel" last="Voss">Daniel Voss</name>
</author>
<author><name sortKey="Schlake, Thomas" sort="Schlake, Thomas" uniqKey="Schlake T" first="Thomas" last="Schlake">Thomas Schlake</name>
</author>
<author><name sortKey="Thess, Andreas" sort="Thess, Andreas" uniqKey="Thess A" first="Andreas" last="Thess">Andreas Thess</name>
</author>
<author><name sortKey="Kallen, Karl Josef" sort="Kallen, Karl Josef" uniqKey="Kallen K" first="Karl-Josef" last="Kallen">Karl-Josef Kallen</name>
</author>
<author><name sortKey="Stitz, Lothar" sort="Stitz, Lothar" uniqKey="Stitz L" first="Lothar" last="Stitz">Lothar Stitz</name>
</author>
<author><name sortKey="Kramps, Thomas" sort="Kramps, Thomas" uniqKey="Kramps T" first="Thomas" last="Kramps">Thomas Kramps</name>
</author>
</analytic>
<series><title level="j">Nature biotechnology</title>
<idno type="eISSN">1546-1696</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aging (immunology)</term>
<term>Animals</term>
<term>Animals, Newborn</term>
<term>B-Lymphocytes (immunology)</term>
<term>Biotechnology</term>
<term>Cross Protection</term>
<term>Female</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Influenza A virus (genetics)</term>
<term>Influenza A virus (immunology)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Inbred DBA</term>
<term>Molecular Sequence Data</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>RNA, Messenger (genetics)</term>
<term>RNA, Messenger (immunology)</term>
<term>RNA, Viral (genetics)</term>
<term>RNA, Viral (immunology)</term>
<term>Rats</term>
<term>Rats, Inbred Lew</term>
<term>Sus scrofa</term>
<term>T-Lymphocytes (immunology)</term>
<term>Vaccines, Synthetic (genetics)</term>
<term>Vaccines, Synthetic (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (génétique)</term>
<term>ARN messager (immunologie)</term>
<term>ARN viral (génétique)</term>
<term>ARN viral (immunologie)</term>
<term>Animaux</term>
<term>Animaux nouveau-nés</term>
<term>Biotechnologie</term>
<term>Données de séquences moléculaires</term>
<term>Femelle</term>
<term>Furets</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Lymphocytes B (immunologie)</term>
<term>Lymphocytes T (immunologie)</term>
<term>Protection croisée</term>
<term>Rats</term>
<term>Rats de lignée LEW</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris de lignée C57BL</term>
<term>Souris de lignée DBA</term>
<term>Sus scrofa</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins synthétiques (génétique)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Vieillissement (immunologie)</term>
<term>Virus de la grippe A (génétique)</term>
<term>Virus de la grippe A (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term>
<term>RNA, Messenger</term>
<term>RNA, Viral</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term>
<term>ARN viral</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins synthétiques</term>
<term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>ARN messager</term>
<term>ARN viral</term>
<term>Infections à Orthomyxoviridae</term>
<term>Lymphocytes B</term>
<term>Lymphocytes T</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins synthétiques</term>
<term>Vieillissement</term>
<term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Aging</term>
<term>B-Lymphocytes</term>
<term>Influenza A virus</term>
<term>Influenza Vaccines</term>
<term>Orthomyxoviridae Infections</term>
<term>RNA, Messenger</term>
<term>RNA, Viral</term>
<term>T-Lymphocytes</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Animals, Newborn</term>
<term>Biotechnology</term>
<term>Cross Protection</term>
<term>Female</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Inbred DBA</term>
<term>Molecular Sequence Data</term>
<term>Rats</term>
<term>Rats, Inbred Lew</term>
<term>Sus scrofa</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Animaux nouveau-nés</term>
<term>Biotechnologie</term>
<term>Données de séquences moléculaires</term>
<term>Femelle</term>
<term>Furets</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae</term>
<term>Protection croisée</term>
<term>Rats</term>
<term>Rats de lignée LEW</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris de lignée C57BL</term>
<term>Souris de lignée DBA</term>
<term>Sus scrofa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Despite substantial improvements, influenza vaccine production-and availability-remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23159882</PMID>
<DateCompleted><Year>2013</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>30</Volume>
<Issue>12</Issue>
<PubDate><Year>2012</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Nature biotechnology</Title>
<ISOAbbreviation>Nat. Biotechnol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.</ArticleTitle>
<Pagination><MedlinePgn>1210-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nbt.2436</ELocationID>
<Abstract><AbstractText>Despite substantial improvements, influenza vaccine production-and availability-remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petsch</LastName>
<ForeName>Benjamin</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Institute of Immunology, Friedrich-Loeffler-Institut, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schnee</LastName>
<ForeName>Margit</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Vogel</LastName>
<ForeName>Annette B</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lange</LastName>
<ForeName>Elke</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hoffmann</LastName>
<ForeName>Bernd</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Voss</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schlake</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Thess</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kallen</LastName>
<ForeName>Karl-Josef</ForeName>
<Initials>KJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stitz</LastName>
<ForeName>Lothar</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kramps</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName>
<AccessionNumberList><AccessionNumber>ABD95991</AccessionNumber>
<AccessionNumber>ABO21709</AccessionNumber>
<AccessionNumber>ABO21710</AccessionNumber>
<AccessionNumber>ABO21711</AccessionNumber>
<AccessionNumber>ACU65077</AccessionNumber>
<AccessionNumber>ACV82259</AccessionNumber>
<AccessionNumber>CAZ65588</AccessionNumber>
<AccessionNumber>CAZ65589</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>11</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Nat Biotechnol</MedlineTA>
<NlmUniqueID>9604648</NlmUniqueID>
<ISSNLinking>1087-0156</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Biotechnol. 2012 Dec;30(12):1202-4</RefSource>
<PMID Version="1">23222788</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001709" MajorTopicYN="N">Biotechnology</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011917" MajorTopicYN="N">Rats, Inbred Lew</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034421" MajorTopicYN="N">Sus scrofa</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>07</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2012</Year>
<Month>10</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23159882</ArticleId>
<ArticleId IdType="pii">nbt.2436</ArticleId>
<ArticleId IdType="doi">10.1038/nbt.2436</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Clin Pharmacol Ther. 2007 Dec;82(6):745-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17971813</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Mol Med. 2006;127:23-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16988444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2006 Nov;24(11):1377-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17093488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3877-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19237568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Berl Munch Tierarztl Wochenschr. 2010 Jul-Aug;123(7-8):286-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20690540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2012 Jan 29;18(2):274-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22286307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Handb Exp Pharmacol. 2008;(183):221-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18071662</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2001 Aug 14;19(31):4479-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11483274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Aug;84(15):7662-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20484500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2008 Aug 1;47(3):401-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18558875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(1):e29732</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22238645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gene Med. 2012 Jun;14(6):428-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22262664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(3):e32400</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22427834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2009 Sep;90(Pt 9):2119-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19592456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 1996 Feb;15(2):121-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8801083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Biotechnol. 2007 Dec;18(6):529-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18083548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1983 Jul 7;309(1):13-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6602294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Feb 23;5(2):e9349</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20186321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1984 Dec 6-12;312(5994):548-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6150440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1993 Mar 19;259(5102):1745-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8456302</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2005 Sep;23(9):1059-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16151391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2008 Aug;7(6):783-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18665776</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Dec 17;25(52):8833-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18023942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br Med Bull. 1979 Jan;35(1):69-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">367490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Feb 8;30(7):1297-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22207090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 May;84(9):4442-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20181699</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunother. 2011 Jan;34(1):1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21150709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Biotechnol. 2008 Dec;26(12):659-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18977045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2006 May;7(5):449-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16622432</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 2000 Jan;30(1):1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10602021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2009 Feb 6;136(3):402-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19203576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2010 Nov 18;363(21):2036-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21083388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4269-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22371588</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2006 Sep 1;177(5):2888-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16920924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2010 Dec;16(12):1389-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21135852</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2010 Oct 29;33(4):504-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21029961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2009 Mar 15;182(6):3469-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19265125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1997 Feb 15;158(4):1507-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9029084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2000 May;61(1):94-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10745239</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20689501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000545 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000545 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:23159882
   |texte=   Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:23159882" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021

	Serveur d'exploration Stress et Covid
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Stress et Covid

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki